Table 1.
Month | Groups | Number of subjects | Age | MMSE | CDR-SOB | CDR-GLOB | ADAS-cog |
---|---|---|---|---|---|---|---|
0 | NC | 226 (M/F: 122/104) | 75.4 ± 7.0 | 29.1 ± 1.0 | 0.0 ± 0.1 | 0.0 ± 0.0 | 6.2 ± 2.9 |
MCI | 393 (M/F: 231/162) | 75.3 ± 6.9 | 27.0 ± 1.8 | 1.0 ± 0.8 | 0.5 ± 0.0 | 11.6 ± 4.4 | |
AD | 186 (M/F: 117/69) | 75.4 ± 6.5 | 23.3 ± 2.0 | 3.3 ± 1.4 | 0.7 ± 0.3 | 18.6 ± 6.3 | |
12 | NC | 201 (M/F: 106/95) | 75.0 ± 7.1 | 29.2 ± 1.1 | 0.1 ± 0.2 | 0.0 ± 0.1 | 5.5 ± 2.8 |
MCI | 351 (M/F: 214/137) | 75.2 ± 6.9 | 26.3 ± 3.0 | 1.6 ± 1.3 | 0.5 ± 0.2 | 12.6 ± 6.2 | |
AD | 149 (M/F: 90/59) | 75.5 ± 6.3 | 21.3 ± 4.3 | 4.5 ± 2.3 | 1.0 ± 0.5 | 22.3 ± 8.8 | |
24 | NC | 192 (M/F: 100/92) | 75.0 ± 7.2 | 29.1 ± 1.1 | 0.1 ± 0.4 | 0.1 ± 0.2 | 5.8 ± 3.0 |
MCI | 289 (M/F: 179/110) | 75.3 ± 7.0 | 25.4 ± 4.0 | 2.2 ± 1.9 | 0.6 ± 0.3 | 14.1 ± 7.5 | |
AD | 122 (M/F: 73/49) | 75.5 ± 6.1 | 19.3 ± 5.6 | 6.0 ± 3.0 | 1.3 ± 0.6 | 27.4 ± 11.3 | |
36 | NC | 172 (M/F: 93/79) | 74.8 ± 7.4 | 29.0 ± 1.3 | 0.1 ± 0.5 | 0.1 ± 0.2 | 5.3 ± 2.9 |
MCI | 221 (M/F: 133/88) | 75.6 ± 7.1 | 24.9 ± 4.6 | 2.6 ± 2.3 | 0.7 ± 0.5 | 15.0 ± 8.8 | |
AD | 9 (M/F: 8/1) | 73.8 ± 4.2 | 17.4 ± 6.6 | 9.0 ± 3.0 | 1.9 ± 0.6 | 30.0 ± 12.7 | |
48 | NC | 51 (M/F: 29/22) | 75.0 ± 7.4 | 29.2 ± 1.1 | 0.1 ± 0.3 | 0.1 ± 0.2 | 6.4 ± 2.8 |
MCI | 50 (M/F: 33/17) | 74.9 ± 6.9 | 24.6 ± 4.3 | 2.9 ± 2.3 | 0.7 ± 0.4 | 14.8 ± 7.3 | |
AD | 2 (M/F: 1/1) | 75.0 ± 0.0 | 21.0 ± 5.7 | 6.0 ± 4.2 | 1.5 ± 0.7 | 20.0 ± 8.0 |
Age, MMSE, CDR-SOB, CDR-GLOB, and ADAS-cog are listed as mean ± standard deviation.
Key: AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s disease assessment scale–cognitive subscale; CDR-GLOB, clinical dementia rating–global; CDR-SOB, clinical dementia rating–sum of boxes; F, female; M, male; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NC, normal control.